Drug Database
LI

lidocaine (lidocaine, Noven / TMADS, Noven / DentiPatch)

✓ Approved

Hisamitsu · SCN9A · 小分子

什么是 lidocaine?

lidocaine 是一种小分子,由Hisamitsu研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名lidocaine, Noven, TMADS, Noven, DentiPatch
公司Hisamitsu
药物类别小分子
分子靶点SCN9A
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

作用机制

分子靶点

lidocaine 作用于 1 个分子靶点:

SCN9Asodium voltage-gated channel alpha subunit 9 (SFNP, GEFSP7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lidocaine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAnaesthesia✓ Approved
Nervous system disordersSensory loss✓ Approved

相关研究文献

PubMedBMC oral health2026-11-17

Analgesic efficacy of 0.75% ropivacaine versus 2% lidocaine after unilateral mandibular third molar extraction: a prospective observational cohort study.

Lin Meiyi M, Yang Yi Y, Ouyang Manting M, Kuang Wei W et al.

This prospective observational cohort study aimed to evaluate the clinical efficacy of 0.75% ropivacaine in unilateral mandibular third molar extraction and to compare its postoperative analgesic outcomes with those of 2% lidocaine. A total of 128 patients undergoing unilateral mandibular third molar extraction were prospectively enrolled. According to the local anesthetic administered during routine clinical practice, patients were categorized into two exposure cohorts: 2% lidocaine (China Otsuka, Tianjin, China) and 0.75% ropivacaine (Shijiazhuang No.4 Pharmaceutical, Shijiazhuang, China). All patients received inferior alveolar nerve block anesthesia with the designated agent, supplemented with local infiltration anesthesia using articaine (Primacaine, Mérignac, France). Postoperative assessments were conducted at 24 h and 7 days using standardized electronic questionnaires. Key measures included: (1) onset of postoperative pain (primary endpoint); (2) duration of lower lip numbness; (3) time to first analgesic intake; (4) 10 cm Visual Analogue Scale (VAS) at 24 h and 7 days; (5) Postoperative Symptom Severity scale (PoSSe). The cohort included 41 males and 82 females, with a mean age of 28.5 ± 7.61 (ranging: 17‒65 years). In ropivacaine group, the Median (Quartile) of postoperative pain onset, durations for lower lip numbness, and time to first analgesic intake were 9.00 (6.00, 11.00) hours, 8.00 (6.00, 9.00) hours, and 7.00 (6.00, 10.00) hours respectively, compared to 3.00 (3.00, 4.00) hours, 3.00 (2.25, 3.00) and 3.00 (2.00, 5.00) hours in lidocaine group. No significant difference was found in both VAS scores at 24 h (24hVAS) and 7 days (7dVAS). No significant difference was found in PoSSe. Only the 24hVAS showed a positive correlation with the Pell & Gregory II classification in both lidocaine group and ropivacaine group. The 7dVAS only showed a positive correlation with the Pell & Gregory II classification in lidocaine group, and the PoSSe only showed a positive correlation with the Pell & Gregory I classification in ropivacaine group (P < 0.05, r > 0). The results demonstrate that 0.75% ropivacaine delays pain onset and analgesic consumption, which may offer an advantageous option for prolonged surgical procedures and early postoperative pain management. However, all patients received supplementary articaine infiltration, which may limit the interpretation of the true analgesic efficacy of the tested agents. Besides, it requires confirmation in randomized trials.

PMID 43040306
阅读全文 →
PubMedJournal of oral rehabilitation2026-11-17

Oral Sensory Loss Alters Masticatory Amplitude but Not Rhythm.

Espinoza Sebastian S, Samson Klaus K, Jiménez Sebastián S, El-Deredy Wael W

Masticatory motor control relies on a delicate balance between central rhythmic patterning and peripheral somatosensory feedback. How these systems adapt to sensory disruption remains unclear. To investigate how transient unilateral reduction of superficial oral somatosensory input-via topical lidocaine-influences human masseter muscle activity and chewing rhythm. In a within-subject crossover design (N = 34), we recorded masseter electromyograms (EMG) during four consecutive chewing bouts following the application of topical anaesthesia or a placebo. This design captured the immediate effects of maximal anaesthesia and its subsequent pharmacological washout. At maximal anaesthesia, masseter EMG amplitude and cycle-to-cycle regularity transiently increased. This compensatory gain was highly lateralized, occurring on the working-side masseter, and decayed across subsequent bouts mirroring lidocaine clearance. In contrast, masticatory rhythm-including chewing rate, cycle duration, and bilateral synchrony-remained remarkably stable and satisfied formal equivalence criteria. There is a clear hierarchical dissociation between motor gain and timing during human chewing. A brainstem central pattern generator preserves the fundamental chewing rhythm, while superficial sensory feedback dynamically calibrates muscle contraction amplitude as a homeostatic sensorimotor compensation.

PMID 43040583
阅读全文 →
PubMedEmergency medicine clinics of North America2026-11-16

Pain Management in the Trauma Patient.

Coughlin Ryan F RF, Couturier Katherine K

Effective pain management in adult trauma patients is essential to improve recovery, reduce complications, and prevent long-term consequences such as chronic pain, depression, and PTSD. Multimodal analgesia combines medications and nonpharmacologic strategies to achieve better pain control while minimizing opioid use and associated risks. Key agents include acetaminophen, nonsteroidal anti-inflammatory agents, ketamine, topical and systemic lidocaine, gabapentinoids, muscle relaxants, and carefully selected opioids when necessary. Pain management should be individualized based on patient factors, including age, comorbidities, traumatic brain injury, and substance use disorders. Early assessment, regular reassessment, and coordinated multidisciplinary care optimize outcomes across trauma settings.

PMID 43039519
阅读全文 →
PubMedEuropean heart journal. Case reports2026-11-16

Severe neonatal long QT syndrome type 3 treated with genotype-directed therapy and early left cardiac sympathetic denervation: a case report.

Greco Andrea A, Martínez-Barrios Estefanía E, Lujan Agustín A, Larrea Óscar Campuzano ÓC et al.

Long QT syndrome type 3 may present in foetal or neonatal life with QT prolongation, 2:1 atrioventricular (AV) block, and life-threatening ventricular arrhythmias. Early recognition and individualizes genotype-directed management may be lifesaving. A neonate delivered after foetal bradycardia and intermittent 2:1 AV block presented with severe QT prolongation and recurrent torsades de pointes. The functional 2:1 AV block persisted despite beta-blockade and magnesium administration. Because of recurrent ventricular arrhythmias, video-assisted thoracoscopic left cardiac sympathetic denervation (LCSD) and implantable loop recorder were performed on Day 8 of life. Genetic testing identified a de novo likely pathogenic SCN5A_p.(Ala1656Val) missense variant. Subsequent lidocaine testing demonstrated marked QT shortening, supporting sodium channel-mediated disease and guiding treatment with mexiletine and flecainide. Long-term follow-up required implantable cardioverter-defibrillator therapy, but arrhythmic burden progressively improved. This case supports the potential role of early multimodal treatment in malignant neonatal long QT syndrome type 3, combining LCSD, continuous rhythm monitoring, and genotype-directed sodium channel blockade.

PMID 43038055
阅读全文 →
PubMedJournal of medical case reports2026-11-16

Refractory ventricular tachyarrhythmia following a suicidal massive caffeine overdose: a case report and review of emergency management.

Negahdari Taha T, Zadehbagheri Fatemeh F, Bornapour Saman S, Yazdanpanah Mohammad M et al.

Caffeine is one of the most widely consumed psychoactive substances worldwide and is readily accessible in tablet formulations and caffeinated beverages. Although moderate caffeine intake is generally considered safe, massive acute ingestion can result in severe toxicity involving the central nervous and cardiovascular systems. Life-threatening manifestations include seizures, profound electrolyte disturbances, metabolic derangements, and malignant ventricular arrhythmias. Because caffeine has favorable dialyzable properties, including low molecular weight, low protein binding, and a relatively small volume of distribution, extracorporeal toxin removal may play a critical therapeutic role in severe intoxication refractory to conventional supportive and antiarrhythmic management. We report the case of a previously healthy 16-year-old Iranian adolescent girl who intentionally ingested 10.8 g of caffeine in a suicide attempt. Approximately two hours after ingestion, she presented with markedly reduced consciousness, agitation, generalized tremor, intermittent tonic/myoclonic seizure-like activity, sinus tachycardia (180-190 beats/min), hypokalemia (serum potassium 2.7 mEq/L), primary metabolic acidosis, significant rhabdomyolysis, and electrocardiographic abnormalities including mild QRS widening and QTc prolongation (~ 500 ms). Urine toxicology screening was positive for caffeine, supporting the diagnosis in conjunction with the clear ingestion history and subsequent patient confirmation. Despite early airway protection, gastrointestinal decontamination, electrolyte and acid-base correction, dual antiarrhythmic therapy with amiodarone and lidocaine, and repeated synchronized electrical cardioversion, she developed recurrent refractory sustained ventricular tachycardia, transient progression to asystole requiring cardiopulmonary resuscitation, and persistent severe metabolic instability. Emergency intermittent hemodialysis was initiated approximately 3-4 h after emergency department arrival, resulting in rapid correction of metabolic acidosis, complete cessation of malignant ventricular arrhythmias, and sustained restoration of stable sinus rhythm. The patient subsequently demonstrated progressive neurological recovery without persistent cardiac or neurological sequelae. This case highlights the potentially catastrophic cardiovascular consequences of massive caffeine intoxication and emphasizes the importance of early recognition, aggressive supportive care, rapid correction of metabolic abnormalities, and timely escalation to extracorporeal toxin removal in refractory cases. In patients with persistent malignant ventricular arrhythmias despite optimized pharmacologic and electrical management, intermittent hemodialysis may represent a life-saving therapeutic intervention capable of rapidly reversing toxicity and improving clinical outcomes.

PMID 43035483
阅读全文 →
PubMedFrontiers in pain research (Lausanne, Switzerland)2026-11-15

Hypertonic dextrose prolotherapy and combined corticosteroid injection for lateral epicondylalgia: a comparative study.

Li Xiao X, Huang Bin B, Huang Guilian G, Ou Zhaoxing Z

Corticosteroid injection offered short-term efficacy for lateral epicondylalgia (LE) but limited long-term benefit, whereas hypertonic dextrose prolotherapy (HDPrT) yields superior medium-to-long-term outcomes. This study aimed to compare the efficacy of hypertonic dextrose prolotherapy combined with corticosteroid injection (HDPrT-C) versus HDPrT in the treatment of LE. Patients receiving ultrasound-guided HDPRT-C or HDPrT from May 2022 to December 2023 were retrospectively enrolled. HDPrT-C group received intratendinous injections of hypertonic dextrose and lidocaine, combined with peritendinous injections of corticosteroid and lidocaine. HDPrT group received only hypertonic dextrose and lidocaine. Patient assessments, including visual analogue scale (VAS) scores, tendon thickness, and tendon blood supply grade, were conducted at baseline, 1, 4, 12, and 24 weeks. 42 patients with LE were included, of whom 50% received HDPrT-C. HDPrT-C group significantly reduced the VAS scores and tendon thickness at short-term (1 and 4 weeks) follow-up compared to HDPrT (P < 0.05), while no statistically significant intergroup difference was observed in the improvement of tendon blood supply grade. At medium-term (12 weeks) follow-up, the tendon thickness in the HDPrT-C group was higher than that in the HDPrT group (mean difference, 0.2 mm; 95%CI: 0.09-0.39, P < 0.05). At long-term (24 weeks) follow-up, HDPrT-C group showed reductions in tendon thickness and improvements in tendon blood supply grade compared to HDPrT group (P < 0.05). No statistically significant intergroup difference was observed in the improvements of VAS scores at 12 weeks and 24 weeks. Compared with HDPrT, HDPrT C produced superior short term pain relief and greater reduction of tendon thickness in LE patients. Definitive medium- and long-term comparative efficacy warrant further investigation in larger trials.

PMID 43031937
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lidocaine